CG Oncology Inc.(CGON)

$79.81—

Chart

CG Oncology Inc.(CGON)

NASDAQ

$79.81—

Chart Studio

CGON(CGON)

CGON

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.86

Nov 13, 2026 · Reports before open

Revenue Estimate

$547,684

FY2029E EPS$2.66

FY2030E EPS$6.30

Analyst Sentiment

Wall St. Consensus

Buy

10 analysts·Moderate coverage

Score

10 Buy (100%)0 Hold (0%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

10100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$80.00

+0.2%

Consensus

$85.00

+6.5%

Bull

$100.00

+25.3%

12-Month Target Range10 analysts

$80.00$85.00$100.00

Current $79.81Consensus

Current Price

$79.81

Upside to Consensus

$5.19

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+1783.88%

EPS—

FY2028

Rev+384.46%

EPS—

FY2029

Rev+138.29%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$4M	$81M	$391M	$931M	$1.52B
Low	$2M	$9M	$121M	$256M	$416M
High	$12M	$148M	$588M	$1.52B	$2.47B
EBITDA Avg	$-4M	$-81M	$-391M	$-931M	$-1.52B
Low	$-12M	$-148M	$-588M	$-1.52B	$-2.47B
High	$-2M	$-9M	$-121M	$-256M	$-416M
EBIT Avg	$-4M	$-81M	$-391M	$-931M	$-1.52B
Low	$-12M	$-148M	$-588M	$-1.52B	$-2.47B
High	$-2M	$-9M	$-121M	$-256M	$-416M
Net Income Avg	$-255M	$-273M	$-85M	$206M	$487M
Low	$-282M	$-282M	$-199M	$12M	$28M
High	$-227M	$-167M	$53M	$375M	$887M
EPS Avg	$-3.32	$-3.13	$-0.90	$2.66	$6.30
Low	$-3.65	$-3.64	$-2.57	$0.15	$0.36
High	$-2.94	$-2.16	$0.69	$4.85	$11.48
Analysts (Rev / EPS)	10 / 12	10 / 11	12 / 12	10 / 9	6 / 5

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$547,684	$545,350	$25M	$11M	$17M	$24M
Low	$507,114	$89,991	$7M	$3M	$5M	$7M
High	$588,253	$1M	$60M	$27M	$41M	$57M
EBITDA Avg	$-547,684	$-545,350	$-25M	$-11M	$-17M	$-24M
Low	$-588,253	$-1M	$-60M	$-27M	$-41M	$-57M
High	$-507,114	$-89,991	$-7M	$-3M	$-5M	$-7M
EBIT Avg	$-547,684	$-545,350	$-25M	$-11M	$-17M	$-24M
Low	$-588,253	$-1M	$-60M	$-27M	$-41M	$-57M
High	$-507,114	$-89,991	$-7M	$-3M	$-5M	$-7M
Net Income Avg	$-74M	$-75M	$-81M	$-76M	$-69M	$-62M
Low	$-82M	$-85M	$-228M	$-214M	$-195M	$-176M
High	$-56M	$-61M	$-5M	$-5M	$-4M	$-4M
EPS Avg	$-0.83	$-0.85	$-0.91	$-0.86	$-0.78	$-0.71
Low	$-0.93	$-0.97	$-2.58	$-2.43	$-2.22	$-2.00
High	$-0.64	$-0.70	$-0.06	$-0.06	$-0.05	$-0.05
Analysts (Rev / EPS)	7 / 9	7 / 9	3 / 6	3 / 3	3 / 3	6 / 6

Earnings Surprises

Recent Analyst Actions

Aug 7, 2026Truist Financial

CG Oncology price target raised to $85 from $82 at Truist

Target:$85.00

+14.3%from $74.35

Jul 29, 2026H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on CG Oncology (CGON)

Target:$100.00

+37.7%from $72.62

May 14, 2026Truist Financial

CG Oncology price target raised to $82 from $77 at Truist

Target:$82.00

+17.1%from $70.00

May 11, 2026RBC Capital

CG Oncology price target raised to $81 from $79 at RBC Capital

Target:$81.00

+14.2%from $70.91

May 11, 2026Wedbush

CG Oncology price target raised to $80 from $77 at Wedbush

Target:$80.00

+14.9%from $69.62

Apr 27, 2026RBC Capital

CG Oncology price target raised to $79 from $73 at RBC Capital

Target:$79.00

+13.8%from $69.42

Mar 26, 2026UBS

CG Oncology price target raised to $90 from $60 at UBS

Target:$90.00

+35.0%from $66.67

Feb 10, 2026Truist Financial

CG Oncology price target raised to $75 from $66 at Truist

Target:$75.00

+40.5%from $53.39

Jan 21, 2026RBC Capital

CG Oncology price target raised to $73 from $61 at RBC Capital

Target:$73.00

+33.5%from $54.69

Jan 16, 2026Piper Sandler

CG Oncology price target raised to $70 from $55 at Piper Sandler

Target:$70.00

+31.9%from $53.07

Jan 12, 2026Goldman Sachs

CG Oncology price target raised to $82 from $55 at Goldman Sachs

Target:$82.00

+51.3%from $54.20

Jan 9, 2026Morgan Stanley

CG Oncology price target raised to $93 from $89 at Morgan Stanley

Target:$93.00

+71.6%from $54.20

Jan 9, 2026Truist Financial

CG Oncology price target raised to $66 from $62 at Truist

Target:$66.00

+21.8%from $54.18

Jan 8, 2026Morgan Stanley

CG Oncology price target raised to $89 from $82 at Morgan Stanley

Target:$89.00

+111.4%from $42.09

Dec 11, 2025Wedbush

CG Oncology initiated with an Outperform at Wedbush

Target:$70.00

+69.5%from $41.30

Nov 24, 2025Truist Financial

CG Oncology initiated with a Buy at Truist

Target:$62.00

+46.1%from $42.44

Nov 17, 2025RBC Capital

CG Oncology price target raised to $61 from $53 at RBC Capital

Target:$61.00

+48.7%from $41.01

Oct 7, 2025Guggenheim

CG Oncology initiated with a Buy at Guggenheim

Target:$90.00

+136.8%from $38.00

Sep 17, 2025Morgan Stanley

CG Oncology price target raised to $79 from $56 at Morgan Stanley

Target:$79.00

+109.4%from $37.72

Aug 19, 2025Piper Sandler

CG Oncology initiated with an Overweight at Piper Sandler

Target:$55.00

+110.4%from $26.14

Mar 7, 2025Morgan Stanley

CG Oncology assumed with an Overweight at Morgan Stanley

Target:$55.00

+105.8%from $26.72

Oct 24, 2024UBS

UBS Starts CG Oncology (CGON) at Buy

Target:$60.00

+68.5%from $35.61

Sep 17, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on CG Oncology (CGON)

Target:$75.00

+97.7%from $37.94

Sep 16, 2024Goldman Sachs

Goldman Sachs Reiterates Buy Rating on CG Oncology (CGON)

Target:$52.00

+49.4%from $34.80

May 13, 2024Goldman Sachs

CG Oncology upgraded to Buy from Neutral at Goldman Sachs

Target:$50.00

+93.5%from $25.84

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance